Medidata Honors Leaders in the Life Sciences Industry at 2023 NEXT Awards
New York – November 21, 2023 Medidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, announced and honored the winners of the 2023 NEXT Awards. The awards recognize biopharmaceutical, medical device companies, and contract research organizations (CROs) excelling in scientific collaboration, sustainability, digital innovation, patient leadership, patient advocacy, and for the first time ever — artificial intelligence (AI) in drug development. They also recognize those in the field making an impact in patient advocacy and driving transformational change in clinical trials.
The awards were presented at Medidata NEXT New York on November 7-8, the signature event that brings together the life sciences leaders who drive innovation and enable tomorrow’s breakthroughs.
“Developing life-transforming treatments is a team effort — it requires the entire life sciences ecosystem to come together to innovate and create monumental change in the clinical trials space,” said Michael Pray, Chief Operating Officer, Medidata. “We are honored to work with companies and individuals who share our values of tenacity, integrity, and inclusion, and our commitment to patients. These well-deserved 2023 NEXT Awards are just one way that we can recognize and honor these leaders for the incredible work that they do to improve the lives of patients.”
Medidata’s 2023 NEXT award winners include:
Collaboration of the Year Award
- Allucent advanced its end-to-end clinical trial operations and achieved faster study build times, improved enrollment, and greater efficiency by using Medidata Rave.
- Bayer invested in DCT technology to design next generation patient-centric studies and created two arms to bring flexibility and meet patients’ needs, a huge commitment to inclusivity. The company also embraced an end-to-end solution resulting in a streamlined experience and leveraged perspectives from Medidata’s Patient Insights Board.
- Novartis implemented an environmental sustainability criterion for their suppliers, including Medidata, to ensure that third-party entities are held responsible for their environmental impact.
Digital Innovation Award
- Fortrea has led the way in shifting the clinical trials landscape from randomized control trials to real-world evidence trials and has collaborated with Medidata to create a template for future studies.
- Immunovant adopted Medidata AI Intelligent Trials, which offered the company opportunities to assess country and site enrollment performance by providing real-time data with limited datasets for rare disease populations. Utilization of the data allowed the Immunovant team to enhance enrollment prediction.
Patient Leadership Award
- Agios and Medidata collaborated on their sickle cell program to design a study with 28 languages, licensing services for 6 instruments, and device provisioning across 16 countries. Agios has leveraged the Medidata Platform for over 10 years to execute clinical trials for rare diseases with a high patient need and is committed to learning from and engaging with patients before, during, and after the clinical trial process.
AI in Support of Drug Development
- Catalyst is the first growth CRO to fully adopt Medidata AI Intelligent Trials. Through this technology, Catalyst is able to utilize 20 years of Medidata’s site performance data to help with more accurate, data driven site selection. This effort ultimately leads to better outcomes for sponsors and patients as this helps select the right sites, at the right time.
- AstraZeneca is challenging the limits within imaging and determining how it can access more data, enhance the analysis of images, and drive imaging technologies at an accelerated pace with the goal of beating lung cancer. With robust imaging platform capabilities, AstraZeneca is partnering with Medidata to offer diagnostic support to radiologists and advance the research and development of cancer treatments.
Glen de Vries Epic Award
- Bunny Ellerin is a distinguished healthcare entrepreneur, advisor, and a driving force in New York City’s transformation into a thriving hub of healthcare innovation. She is the co-founder and CEO of Digital Health New York (DHNY), a connected community that shares ideas, sparks new directions, and creates success across the entire digital health ecosystem.
Linnea Olson Award for Patient Advocacy
- Jamie Goldfarb is a devoted patient advocate and clinical trial recruitment specialist who turned her own battle with cancer into a mission for patients. Now the director of patient recruitment strategy at Trialbee, Jamie works to make clinical trial information accessible for patients and advising the medical community and life sciences industry about the patient experience.